Related Experiment Video
Updated: May 24, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Isolated regional therapy for advanced extremity soft tissue sarcomas
Jeremiah L Deneve1, Jonathan S Zager
1Cutaneous Oncology Department, Moffitt Cancer Center, Tampa, FL 33612, USA.
Surgical Oncology Clinics of North America
|February 28, 2012
Summary
Isolated regional perfusion therapies, including hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI), offer effective limb salvage for unresectable extremity sarcomas. These treatments show encouraging response and limb preservation rates with manageable toxicity.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Unresectable, large, primary or recurrent extremity soft tissue sarcomas pose significant treatment challenges.
- Amputation is often considered for advanced extremity tumors, necessitating limb salvage alternatives.
Purpose of the Study:
- To evaluate the efficacy and toxicity of isolated regional perfusion therapies for extremity soft tissue sarcomas.
- To explore the role of hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) as definitive or neoadjuvant treatments.
Main Methods:
- Review of isolated regional perfusion techniques, specifically HILP and ILI.
- Analysis of treatment outcomes including response rates and limb preservation in patients with advanced extremity tumors.
Main Results:
- HILP and ILI demonstrate efficacy in managing unresectable extremity soft tissue sarcomas.
- These regional therapies show acceptable systemic and regional toxicity profiles.
- Encouraging response and limb preservation rates were observed.
Conclusions:
- Isolated regional perfusion therapies are valuable limb salvage options for unresectable extremity sarcomas.
- Further multicenter collaborations and clinical trials are needed to expand indications and optimize treatment protocols for advanced soft tissue sarcomas.
